International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder CancerM. Roumiguié, Peter C. Black, Wassim Kassouf et al.|European Urology|2021Cited by 94
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer GroupAshish M. Kamat, Matthew D. Galsky, Andrea B. Apolo et al.|Journal of Clinical Oncology|2023Cited by 55